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Available online 7 May 2016Introduction: Aldosterone seems to inﬂuence the haemostatic system by several mechanisms and to increase the
risk of thrombosis. The objective of this meta-analysis was to assess the impact of inhibition of the mineralocor-
ticoid receptor due to the use ofmineralocorticoid receptor antagonists (MRAs) on venous and arterial thrombo-
sis, bleeding events and mortality.
Materials and methods:We systematically searched PubMed and EMBASE through August 1, 2014, without lan-
guage restrictions. Randomised controlled trials (RCTs) that tested the effect of MRAs versus active control/no
treatment and reported data on thrombotic or bleeding events or mortality in patients with common causes of
secondary hyperaldosteronism were included.
Results: 20 published RCTs reported in 19 papers for a total of 17,610 patients met inclusion criteria. Of these, all
reported data on mortality, 15 on cardiovascular mortality, 14 on thrombotic events and 12 reported data on
bleeding events. NoRCTs investigatedpatientswith primaryhyperaldosteronism. 19RCTswere performed inpa-
tients with hypertension and heart failure. In general, the heterogeneity was low. No differences were observed
in arterial thrombotic and bleeding events. Patients treatedwithMRAs had 20% lower odds of totalmortality and
23% of cardiovascularmortality comparedwith controls (odds ratio (OR) 0.80, 95% conﬁdence interval (CI) 0.73–
0.87 and OR 0.77, 95% CI 0.70–0.85, respectively).
Conclusion: Inhibition of the mineralocorticoid receptor with MRAs in patients with hypertension and heart fail-
ure does not change the risk ofmyocardial infarction, stroke and bleeding events. Ourmeta-analysis conﬁrms the
favourable effects ofMRAs on total and cardiovascularmortality. These data suggest thatMRAs can be considered
as safe regarding their effects on haemostasis in patients with hypertension and heart failure.
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Both altered coagulation and ﬁbrinolysis markers and thrombotic
disorders have been described in several endocrine diseases. One of
the hormones of interest is aldosterone, a steroid hormone produced
by the adrenal glands, endothelial cells, vascular smoothmuscle cells
and, locally, in tissues such as the brain and the heart muscle [1]. It
mainly acts to conserve sodium (and with it, water) and to promote
potassium excretion. Several mechanisms have been suggested by
which aldosterone interacts with the cardiovascular (CV) system in-
creasing the risk of CV disease: it may promote endothelial dysfunc-
tion, reduce vascular compliance, impair baroreceptor function and
causemyocardial and vascular ﬁbrosis [2]. There are limited and con-
tradictory data of aldosterone on coagulation and ﬁbrinolysis but it is
suggested that the net effect of aldosterone promotes a pro-
coagulant state [3–7]. In a retrospective case–control study, com-
pared to patients with essential hypertension, the risk of stroke
was 4-fold in primary hyperaldosteronism and the risk of non-fatal
myocardial infarction (MI) 6.5-fold [8]. Considering these data, it's pos-
sible that the positive effect of mineralocorticoid receptor antagonists
(MRAs) may be, partially, mediated by an effect on haemostasis. It is
also possible that inhibiting aldosterone with MRAs could lead to a
bleeding risk. This was suggested by a population based case–control
study that showed an increased risk of gastrointestinal bleeding in pa-
tients using spironolactone [9]. Meta-analyses have explored the effect
of MRAs on mortality, heart failure including its associated comorbidi-
ties and blood pressure. Analyses assessing the effect of inhibition of
the mineralocorticoid receptor due to MRA use on thrombotic and
bleeding events in patients with primary hyperaldosteronism and/or
common causes of secondary hyperaldosteronism have been lacking.
Accordingly, we attempted to conduct a meta-analysis of existing
randomised controlled trials (RCTs) of MRAs compared to placebo or
control used in patients with primary or common causes of secondary
hyperaldosteronism with the hypothesis that MRAs could affect the
haemostatic system and thereby may decrease the risk of thrombosis
and increase the risk of bleeding events. Our secondary objective was
to conﬁrm the favourable effects of MRAs on mortality.2. Materials and methods
We performed a systematic review and meta-analysis of RCTs of
MRAs in patients with primary hyperaldosteronism or conditions thatare associated with secondary hyperaldosteronism, according to the
PRISMA guidelines [10].
2.1. Data sources
We conducted a systematic search of the major scientiﬁc databases
PubMed (MEDLINE) and EMBASE without language restrictions
through August 1, 2014, for RCTs (for keywords please refer to Supple-
mentary data). In addition, we searched references of the included
manuscripts.
2.2. Study selection
We included RCTs that met the following criteria: enrolment of pa-
tients with primary or common causes of secondary hyperaldosteronism
(heart failure or left ventricular dysfunction, hypertension, liver cirrhosis
withportal hypertension); randomisationof patients toMRA therapy ver-
sus placebo or no active treatment on top of standard therapy (control
group); reporting data or corresponding author providing additional
data on either one of the following: total and CV mortality, thrombotic
or bleeding events and study duration ≥4 weeks. In case of a cross-over
design the minimal washout period had to be 2 weeks. Imaging tech-
niques and standardiseddiagnostic tools for assessment of venous throm-
boembolic events came into use from 1990 onwards and therefore we
solely included RCTs from 1990.
2.3. Data extraction and quality assessment
Two reviewers (L.E. and B.S.) independently screened the abstracts
of all the citations obtained by the search in a standardized and unblind-
ed manner. The outcomes of both independent screenings were
discussed and discrepancies were resolved by consensus. Full texts of
studies that met inclusion criteria were retrieved for secondary data ex-
traction using a standardized form that included baseline patient char-
acteristics, study design, risk of bias, MRAs, primary and secondary
outcomes. Primary outcome of our systematic review was the occur-
rence of thrombotic events including fatal and non-fatal MI, fatal and
non-fatal stroke, fatal and non-fatal acute limb ischaemia, fatal and
non-fatal pulmonary embolism (PE), deep venous thrombosis (DVT),
unusual site venous thrombosis, (i.e. splanchnic vein thrombosis), and
other arterial and venous thrombotic events. Secondary outcomes
were the occurrence of total and CV mortality and minor and major
bleeding events. Criteria for major bleedings were according to the
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[11]. All other bleeding events were noted as minor bleedings. The cor-
responding authors of the included studies were contacted for provid-
ing additional data. Risk of bias was assessed according to the
Cochrane Collaboration Risk of Bias Tool [12]. Disagreement between
the 2 reviewers was resolved by consensus and secondary review
from one of the other investigators.
2.4. Statistical analysis
Statistical analysis was performed using Review Manager 5.2 [13]
and extracted in accordance with intention to treat-analysis. We calcu-
lated the summary odds ratio (OR) and 95% conﬁdence interval (CI) for
the outcome variables by using Mantel–Haenszel ﬁxed effects model.
Randomeffectsmodelwas used in case of signiﬁcant heterogeneity. Sta-
tistical heterogeneitywasmeasured by the I [2] statistic. A priori, we de-
ﬁned signiﬁcant heterogeneity between trials as an I [2] value of N30%
(N30 and ≤50% as intermediate heterogeneity with N50% as high het-
erogeneity). Clinical heterogeneity between the trials was explored by
using subgroup analysis on the patient population, MRA agent and dos-
age used.Fig. 1. Flow diagram o3. Results
3.1. Study selection
Our search strategy yielded 2514 studies (Fig. 1). The full texts of 61
studies were assessed for eligibility. 13 were excluded for the reasons
depicted in Fig. 1 (references available on request). Finally, 20 RCTs re-
ported in 19 papers, for a total of 17,610 patients, met our inclusion
criteria [14–32]. The study characteristics of all included RCTs are sum-
marized in Tables 1 and 2.
3.2. Available data
5 RCTs reported ≥1 our outcomes of interest as a primary outcome
(Table 2), 19 RCTs described ≥1 outcome of interest in their result sec-
tion including the description of serious adverse events and, ﬁnally, cor-
responding authors of 7 RCTs provided additional data on outcomes of
interest. Data on fatal and non-fatal MI were available in 15 RCTs for a
total of 16,956 patients. Data on fatal and non-fatal stroke were avail-
able in 14 RCTs for a total of 16,851 patients. Data on our other primary
outcomeswere available in 11 RCTs for a total of 10,202 patients, exceptf study selection.
Table 1
Characteristics of included studies.
Source Patients MRA
(n)
Control
(n)
MRA Drug
control
Mean follow-up
(months)
Akbulut 2003 [14] NYHA class III HF 35 35 Spironolactone 25 mg od Control 12 weeks
Boccanelli 2009 [15] NYHA class II HF with low EF 231 236 Canrenone 25–50 mg od Placebo 12
Bolondi 2006 [16] Child-Pugh A viral pre-ascitic cirrhosis with portal
hypertension
66 54 Kcanrenoate 100 mg/day Placebo 52 weeks
Calhoun 2011 [17] Primary hypertension 84 77 Eplerenone 50 mg td Placebo 8 weeks
Cicoira 2002 [18] NYHA class I–III HF 54 52 Spironolactone 12.5–50 od Control 12
Deswal 2011 [19] NYHA class II or III HfpEF 23 23 Eplerenone 25 to 50 mg/day Placebo 24 weeks
Edelmann 2013 [20] NYHA class II or III HF, preserved LVEF of ≥50% and
diastolic dysfunction
213 209 Spironolactone 25 mg od Placebo 12
Krum 2002 [21] Uncontrolled hypertension despite ACEI/ARB 170 171 Eplerenone 50–100 mg od Placebo 8 weeks
Oxlund 2013 [22] Type 2 diabetes with BP ≥130/80 mm Hg despite triple
therapy
61 58 Spironolactone 25 mg od-td Placebo 16 weeks
Pitt 2014 [24] Symptomatic HF and LVEF ≥45% 1722 1723 Spironolactone 15 mg to 45 mg daily Placebo 3.3 years
Pitt 2013 part A [23] HFrEF and mild CKD 49 16 BAY 94–8862 2.5–10 mg od Placebo 4 weeks
Pitt 2013 part B [23] HFrEF and moderate CKD 328 65 BAY 94–8862 2.5–10 mg od or 5 mg td or
spironolactone 25 or 50 mg od
Placebo 4 weeks
Pitt 2003 [25] AMI complicated by LV dysfunction and HF 3313 3319 Eplerenone 25 to 50 mg/day Placebo 16
Pitt 1999 [26] Severe HF with LVEF ≤35% 822 841 Spironolactone 25 mg od Placebo 24
Taheri 2012 [27] CAPD patients with NYHA class III or IV HF, EF ≤45%,
potassium level ≤5.5 mEg/L
9 9 Spironolactone 25 mg every other day Placebo 6
Václavík 2011 [28] Resistant arterial hypertension 59 58 Spironolactone 25 mg od Placebo 8 weeks
Vizzardi 2014 [30] NYHA class I–II HF and LVEF b40% 65 65 Spironolactone 25 mg od to 100 mg 4 times a day Placebo 3.4 years
Vizzardi 2010 [29] NYHA class I/II HF and LVEF ≤40% 79 79 Spironolactone 25–100 mg od Placebo 6
White 2003 [31] Untreated essential hypertension 310 90 Eplerenone 25–200 mg od Placebo 12 weeks
Zannad 2011 [32] NYHA class II HF and EF ≤35% 1364 1373 Eplerenone 25–50 mg od Placebo Median 21
months
ACEI indicates angiotensin-converting-enzyme inhibitor; AMI, acute myocardial infarction; ARB, angiotensin II receptor blocker; BP, blood pressure; CAPD, continuous ambulatory peri-
toneal dialysis; CKD, chronic kidney disease; EF, ejection fraction; HF, heart failure; HfpEF, heart failurewith preserved ejection fraction; HfrEF, heart failure and reduced ejection fraction;
LVEF, left ventricular ejection fraction; MRA; mineralocorticoid receptor antagonist; n, number; NYHA, New York Heart Association; od, once daily; and td, twice daily.
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was not possible to analyse this outcome. Data on total mortality and
on CVmortality were available in 20 RCTs for a total of 17,610 patients,
and in 16 RCTs for a total of 16,861 patients, respectively. Data onmajor
and minor bleeding events were available in 12 RCTs for a total of
10,220 patients, and in 5 RCTs for a total of 8653 patients, respectively.
3.3. MRAs used and follow-up duration
In the RCTs, different types of MRAs were used in different dosages
(Table 1). Spironolactone was used in 11 RCTs and Canrenone and
Kcanrenoate both in 1 RCT. Eplerenone was used in 6 RCTs and BAY
94-8862 (ﬁnerenone) in 2 RCTs. The minimal treatment period was
4 weeks, 14 RCTs had a mean treatment period up to 1 year and the
maximal mean treatment period was 3.4 years.
3.4. Risk of bias assessment
In a substantial amount of RCTs, the risk of selection (13 RCTs), per-
formance (12 RCTs) and detection bias (7 RCTs) was unclear due to
missing information (Supplementary Figs. 1, 2).
3.5. Patient populations in RCTs
There were no RCTs on primary hyperaldosteronism. The patients in
most of the trials were included because of heart failure, and in 5 RCTs,
patients with hypertension were included. One study included patients
with pre-ascitic cirrhosis with endoscopic and/or ultrasound evidence
of portal hypertension. The dropout rate varied from 0 to 13%. The
usage of antithrombotic agents was reported inconsistently (Table 2).
3.6. Thrombotic events
Overall, patients treated with MRAs had similar odds of fatal and
non-fatal MI compared with controls (OR, 0.98; 95% CI, 0.85–1.12;P= 0.76) (Fig. 2, Table 3 for absolute and relative incidences). Patients
who were treated with MRAs had similar odds of fatal and non-fatal
stroke compared with controls (OR, 1.02; 95% CI, 0.83–1.24; P= 0.88)
(Fig. 3). No statistical signiﬁcant differences were found in fatal and
non-fatal acute limb ischaemia, fatal and non-fatal PE, DVT and other ar-
terial and venous thrombotic events when comparing patients who
were treated with MRAs to controls (Supplementary Figs. 3–7).3.7. Bleeding events
Patients treated with MRAs had similar odds of major bleeding
events compared with controls (OR, 1.03; 95% CI, 0.76–1.41; P= 0.85)
(Fig. 4). Besides this, patients who were treated with MRAs had similar
odds of minor bleeding events compared with controls (OR, 0.91; 95%
CI, 0.74–1.11; P= 0.36) (Supplementary Fig. 8).3.8. Total and CV mortality
Patients treated with MRAs had 20% lower odds of death compared
with controls (OR, 0.80; 95% CI, 0.73–0.87; P b 0.00001) and 23% lower
odds of CV death compared with controls (OR, 0.77; 95% CI, 0.70–0.85;
P b 0.00001) (Fig. 5, Supplementary Fig. 9). The absolute risk reduction
for total mortality was 3.8% and for CVmortality it was 3.6% resulting in
a number needed to treat of 27 and 28 patients, respectively.3.9. Subgroup analyses
Subgroup analyses on patient population (heart failure versus hy-
pertension), MRA agent used (spironolactone (±canrenone and
Kcanrenoate), eplerenone and ﬁnerenone) did not change the results
(data not shown). It was not possible to perform subgroup analyses
on MRA dosage used since multiple dosages were used in several stud-
ies and outcomes were not reported per dosage.
Table 2
Characteristics of patient populations in the trials.
Source Age (years mean ± SD)
MRA/control
% male
MRA/
control
Study
centre
type
Primary outcome Type of blinding/randomization Use of
antithrombotic
therapy (%)
MRA/control
Akbulut 2003 [14] 58.9 ± 6.1/59.2 ± 5.3 57.1/53.3 Single QT dispersion −/− ASA (≤325 mg) if
needed
Boccanelli 2009 [15] 62.3 ± 9.5/62.7 ± 9.5 81.8/85.2 Multi Change in echocardiographic LVEDV Double-blind/− Antiplatelets:
57.0/57.1
Other: 23.7/24.8
Bolondi 2006 [16] 60.4 ± 9.5/61.0 ± 8.3 65.2/74.1 Multi Progression of variceal status or
appearance of ascites
Double-blind/computer random number
generator
–
Calhoun 2011 [17] 55.3 ± 9.1/53.9 ± 8.7 66.7/59.7 Multi Mean DBP Double-blind with matching
placebo/IVRS provider
–
Cicoira 2002 [18] 62.5 ± 7.9/61.7 ± 9.8 85.2/88.5 Single LV function and exercise tolerance Response variables evaluated by
physicians blind to treatment group/−
–
Deswal 2011 [19] 72.2 ± 9.8/68.7 ± 9.1 95.2/91.3 Single Change in 6MWD Double-blind with matching placebo/− –
Edelmann 2013 [20] 67 ± 8/67 ± 8 48/47 Multi Diastolic function and maximal exercise
capacity
Double-blind with matching
placebo/Pocock minimization algorithm
If needed
Krum 2002 [21] 55.0/54.9 48.2/46.2 Multi Mean diastolic and systolic BP Double-blind/computer generated
schedule
–
Oxlund 2013 [22] 62.9 ± 7.1/63.9 ± 6.9 75/78 Multi Mean ABPM Double-blind/scheme generated by
Randomization.com
–
Pitt 2014 [24] Median (IQR) 68.7
(61.0–76.4)/
68.7 (60.7–75.5)
48.4/48.5 Multi Death from CV causes, aborted cardiac
arrest, or hospitalization for HF
Double-blind with matching
placebo/permuted blocks
Aspirin: 65.2/65.6
Warfarin:
23.4/22.3
Pitt 2013 part A [23] Mean (range): 67.0
(42–85)/63.9 (50–75)
77.6/87.5 Multi Potassium concentration, eGFR and
albuminuria
Double-blind with placebo/validated
automated system
–
Pitt 2013 part B [23] Mean (range): 72.1
(40–89)/72.4 (51–85)
80.1/76.9 Multi Potassium concentration Double-blind placebo and open-label
spironolactone comparator
arms/validated automated system
–
Pitt 2003 [25] 64 ± 11/64 ± 12 72/70 Multi Death from any cause and CV causes or
hospitalization for HF, AMI, stroke or
ventricular arrhythmia
Double-blind with matching
placebo/permuted blocks
Aspirin: 88/89
Pitt 1999 [26] 65 ± 12/65 ± 12 73/73 Multi Death from any cause Double-blind with matching placebo/− Aspirin: 36/37
Taheri 2012 [27] 50.7 ± 17.4/57.2 ± 13.1 55.6/55.6 Single Potassium levels and EF Double-blind with matching placebo/− –
Václavík 2011 [28] 61.4 ± 9.6/60.1 ± 9.4 67.3/57.1 Multi Fall of systolic and diastolic pressure on
ABPM
Double-blind with matching
placebo/simple randomization
–
Vizzardi 2014 [30] 61 ± 14.7/65 ± 17.4 – Single CV death or hospitalization Single-blind with matching placebo/− –
Vizzardi 2010 [29] 61 ± 13/58 ± 13 84/82 Single LV systolic and diastolic
functions and functional capacity
Single-blind/− –
White 2003 [31] 51–54 ± 9–11/54 ± 11 45.2/40 Multi Mean diastolic BP Double-blind/− –
Zannad 2011 [32] 68.7 ± 7.7/68.6 ± 7.6 77.3/78.1 Multi CV death or hospitalization for HF Double-blind with matching
placebo/computerized system
Antiplatelet or oral
anticoagulant:
88.3/88.4
ABPM indicates blood pressure by ambulatorymonitoring; AMI, acute myocardial infarction; ASA, acetyl salicylic acid; CV, cardiovascular; DPB, diastolic blood pressure; EF, ejection frac-
tion; eGFR, estimated glomerular ﬁltration rate; HF, heart failure; IQR, interquartile range; IVRS, interactive voice response system; LV, left ventricular; LVEDV, LV end-diastolic volume;
MRA, mineralocorticoid receptor antagonist; SD, standard deviation; and 6MWD, 6-minute walk distance.
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In general, the heterogeneity among the trials was low (I2=0–18%),
except for the outcomes fatal and non-fatal acute limb ischaemia,which
had high heterogeneity (I2 = 70%), and fatal and non-fatal PE, with in-
termediate heterogeneity (I2 = 31%).
3.11. Publication bias
In general there is a low risk of publication bias (Supplementary Figs.
11–20).
4. Discussion
In this meta-analysis we systematically reviewed the impact of inhi-
bition of the mineralocorticoid receptor due to the use of MRAs on ve-
nous and arterial thrombosis, bleeding events and mortality in
patients with common causes of secondary hyperaldosteronism (main-
ly hypertension and heart failure). We may conclude that in patients
with hypertension and heart failure, inhibition of the mineralocorticoid
receptor with MRAs did not materially alter the risk of thromboticevents and bleeding events. The favourable effects of MRAs on both
total and CVmortality were conﬁrmed. Our attempt was to also include
RCTs with mainly patients with primary hyperaldosteronism but there
were no such RCTs.
We hypothesized that MRAs could affect the haemostatic system
and thereby may decrease the risk of thrombosis and increase the risk
of bleeding events. This was based on studies which suggested that al-
dosterone inﬂuences the haemostatic system with a net procoagulant
effect [2,5–7]. Experimental studies in rats showed that aldosterone in-
fusion results in a shorter bleeding time, more platelet adhesion, higher
expression of Plasminogen activator inhibitor-1 (PAI-1), more throm-
bus formation [3] and high thrombin activatable ﬁbrinolysis inhibitor
levels implying enlarged thrombin generation [4]. In humans, aldoste-
rone and PAI-1 seem to be correlated [5,6] and treatment with
spironolactone abolished this correlation. Finally, in healthy persons
and in hypertensive patients, spironolactone reduced PAI-1 concentra-
tions compared with triamterene [7]. Besides this, clinical endpoint
studies showed that patients with primary hyperaldosteronism experi-
enced more arterial thrombotic events [8] and that the use of
spironolactone leaded to more gastrointestinal bleeding events [9].
With this meta-analysis we have shown that in patients with hyperten-
sion and heart failure, inhibition of the mineralocorticoid receptor with
Fig. 2. Forest plot comparing fatal and non-fatal myocardial infarction in patients treated with and without mineralocorticoid receptor antagonists. CI indicates conﬁdence interval; M-H,
Mantel-Haenszel; and MRAs, mineralocorticoid receptor antagonists.
37L.P.B. Elbers et al. / Thrombosis Research 144 (2016) 32–39MRAs did notmaterially alter the risk of fatal and non-fatalMI, fatal and
non-fatal stroke or minor and major bleeding events. Other thrombotic
primary outcomes of interest were not reported enough to draw any
conclusions. The under-reporting of relevant clinical outcomes is well-
known problem and a recent meta-analysis of therapeutic RCTs pub-
lished in major clinical journals concluded that the incidence of venous
and arterial thrombosis is highly under-reported [33]. Based on our fun-
nel plots per outcome, there is a suspicion of selective data outcome
reporting, in particular for minor bleeding events and for CV mortality,
but this could also be explained by the low number of RCTs reporting
most of our outcomes of interest.
In this meta-analysis, treatment with MRAs led to signiﬁcant reduc-
tions in total and CV mortality comparable to those reported in other
meta-analyses [34]. Since treatment with MRAs did not reduce the
risk of myocardial and infarction and stroke, it is likely that this reduc-
tion in mortality is mainly due to the effect of MRAs on death from pro-
gressive heart failure and sudden death from cardiac causes. One
explanation for the absence of an observed effect of MRAs on thrombot-
ic events could be that ACE-inhibitors lower levels of PAI-1 [35,36].
Given that the vast majority of the RCTs in this meta-analysis included
patients with left ventricular dysfunction and resistance hypertension,
ACE inhibitor usewould have beenwidespread and this could have ham-
pered the possibility to detect an effect of MRAs on thrombotic events.
There doesn't seem to be an important effect of MRAs on haemostasis in
patients with heart failure and hypertension, although no evidence of
established secondary hyperaldosteronism was provided in the patientsTable 3
Incidences of primary and secondary outcomes in MRA users.
Outcome Absolute incidence
(n)
Relative incidence
(%)
Fatal and non-fatal MI 435 5.0
Fatal and non-fatal stroke 196 2.3
Fatal and non-fatal acute limb ischemia 15 0.3
Other arterial thrombotic events 10 0.2
Fatal and non-fatal PE 13 0.2
DVT 2 0.04
Other venous thrombotic events 18 0.3
Unusual site venous thrombosis 0 0
Major bleeding events 82 1.6
Minor bleeding events 185 4.3
Total mortality 1213 13.4
CV mortality 976 11.3
CV indicates cardiovascular; DVT, deep venous thrombosis; MI; myocardial infarction; N
indicates number; and PE, pulmonary embolism.in the RCTs that we included. Still, the question remains whether this ef-
fect is also absent in patients with primary hyperaldosteronism. Besides
this, if aldosterone truly inﬂuences haemostasis, despite the results of
our meta-analysis, this might be important for patients that are already
at risk for bleeding due to other reasons such as liver dysfunction or the
use of ulcerogenic drugs [9]. We were not able to perform a subgroup
analysis in patients with a higher bleeding risk. We were able to per-
form subgroup analyses based on patient population (heart failure ver-
sus hypertension) and MRA agent used (spironolactone (± canrenone
and Kcanrenoate), eplerenone and ﬁnerenone) and this did not change
our conclusions. One explanation for the absence of an effect of MRAs
on bleeding risk in ourmeta-analysis could be thatMRAs don't suppress
aldosterone enough to detect limited effects of aldosterone on
haemostasis. Although debated due to its design [37], our hypothesis
that the use of MRAs could lead to a higher bleeding risk was partly
based on a population based case–control study which observed that
the use of spironolactone increases the risk of upper gastrointestinal
bleeding [9]. The association increased proportionally with dosage and
was most pronounced when combined with ulcerogenic drugs. Most
of the included RCTs in our meta-analysis were performed in patients
with hypertension and heart failure, which require relatively low dos-
ages of MRAs when compared to patients with portal hypertension
due to liver cirrhosis. Unfortunately, in our meta-analysis, it was not
possible to perform subgroup analyses on MRA dosage used since mul-
tiple dosages were used in several studies and outcomes were not re-
ported per dosage.
Another limitation of this meta-analysis is that the use of antithrom-
botic agents was scarcely reported in the RCTs. However, since this
meta-analysis solely consists of RCTs, any possible bias and confounder,
including the use of antithrombotic agents, should be evenly distributed
between the patients. One could also debate that the RCTs included in
this meta-analysis were not designed to study the effect of MRAs on
thrombosis and bleeding events and therefore the reporting is inconsis-
tent. However, this should also be the same for both groups due to the
design of the included studies and therefore will not inﬂuence the con-
clusion of this meta-analysis. Besides, most of the data on this outcome
were achieved from the reporting of serious adverse events as part of
performing a RCT with a medical drug.
In conclusion, we observed that inhibition of the mineralocorticoid
receptor with MRAs in patients with hypertension and heart failure
did not change the risk ofMI, stroke and bleeding events. This is relevant
for both patients and health care providers considering the high inci-
dence of hypertension and heart failure. Moreover, our meta-analysis
conﬁrms the favourable effects of MRAs on both total and CV mortality.
Fig. 3. Forest plot comparing fatal and non-fatal stroke in patients treated with and without mineralocorticoid receptor antagonists. CI indicates conﬁdence interval; M-H, Mantel-
Haenszel; and MRAs, mineralocorticoid receptor antagonists.
Fig. 4. Forest plot comparing major bleeding in patients treated with and without mineralocorticoid receptor antagonists. CI indicates conﬁdence interval; M-H, Mantel-Haenszel; and
MRAs, mineralocorticoid receptor antagonists.
Fig. 5. Forest plot comparing cardiovascularmortality in patients treatedwith andwithoutmineralocorticoid receptor antagonists. CI indicates conﬁdence interval;M-H,Mantel-Haenszel;
and MRAs, mineralocorticoid receptor antagonists.
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39L.P.B. Elbers et al. / Thrombosis Research 144 (2016) 32–39Besides, this meta-analysis again underlines the under-reporting of
both venous and arterial thrombosis in RCTs and the need for uniform
registration of adverse events, even when unlikely beforehand to be re-
lated to the intervention.
Disclosures
Prof. dr. Zannad reports personal fees from Pﬁzer during the conduct
of the study and personal fees from Janssen, Bayer, Takeda, Novartis,
Boston Scientiﬁc, Resmed, Stealth peptide, Amgen, CVRx, Mistusbishi,
Quantum Genomics, AstraZeneca EliLilly, Relypsa, ZSPharma and
Merck outside the submitted work.
Funding
None.
Acknowledgements
We thank Renaud Fay for collecting additional data on the outcomes
of this meta-analysis. The authors did not have any writing assistance.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.thromres.2016.04.027.
References
[1] N.J. Brown, Eplerenone: cardiovascular protection, Circulation 107 (2003) 2512–2518.
[2] A.D. Struthers, T.M. MacDonald, Review of aldosterone- and angiotensin II-induced
target organ damage and prevention, Cardiovasc. Res. 61 (2004) 663–670.
[3] A. Gromotowicz, J. Szemraj, A. Stankiewicz, A. Zakrzeska, M. Mantur, E. Jaroszewicz,
F. Rogowski, E. Chabielska, Study of the mechanisms of aldosterone prothrombotic
effect in rats, J. Renin-Angiotensin-Aldosterone Syst. 12 (2011) 430–439.
[4] A. Stankiewicz, A. Gromotowicz, J. Szemraj, M. Wojewodzka-Zelezniakowicz, P.
Skrzypkowski, E. Chabielska, Acute aldosterone infusion enhances thrombosis de-
velopment in normotensive rats, Thromb. Haemost. 98 (2007) 697–699.
[5] N.J. Brown, D.E. Vaughan, A.B. Fogo, Aldosterone and PAI-1: implications for renal
injury, J. Nephrol. 15 (2002) 230–235.
[6] P. Sawathiparnich, S. Kumar, D.E. Vaughan, N.J. Brown, Spironolactone abolishes the
relationship between aldosterone and plasminogen activator inhibitor-1 in humans,
J. Clin. Endocrinol. Metab. 87 (2002) 448–452.
[7] J. Ma, F. Albornoz, C. Yu, D.W. Byrne, D.E. Vaughan, N.J. Brown, Differing effects of
mineralocorticoid receptor-dependent and -independent potassium-sparing di-
uretics on ﬁbrinolytic balance, Hypertension 46 (2005) 313–320.
[8] P. Milliez, X. Girerd, P.F. Plouin, J. Blacher, M.E. Safar, J.J. Mourad, Evidence for an in-
creased rate of cardiovascular events in patients with primary aldosteronism, J. Am.
Coll. Cardiol. 45 (2005) 1243–1248.
[9] K. Verhamme, G. Mosis, J. Dieleman, B. Stricker, M. Sturkenboom, Spironolactone
and risk of upper gastrointestinal events: population based case–control study,
BMJ 333 (2006) 330.
[10] D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, P. Group, Preferred reporting items for
systematic reviews and meta-analyses: the PRISMA statement, PLoS Med. 6 (2009)
e1000097.
[11] S. Schulman, C. Kearon, Subcommittee on Control of Anticoagulation of the S,
Standardization Committee of the International Society on T, Haemostasis, Deﬁni-
tion of major bleeding in clinical investigations of antihemostatic medicinal prod-
ucts in non-surgical patients, J. Thromb. Haemost. 3 (2005) 692–694.
[12] J.P. Higgins, D.G. Altman, P.C. Gotzsche, P. Juni, D. Moher, A.D. Oxman, J. Savovic, K.F.
Schulz, L. Weeks, J.A. Sterne, Cochrane Bias Methods G, Cochrane Statistical Methods
G, The Cochrane Collaboration's tool for assessing risk of bias in randomised trials,
BMJ 343 (2011) d5928.
[13] S. Tandon, N. Munir, N.J. Roland, J. Lancaster, S.R. Jackson, T.M. Jones, A systematic
review and number needed to treat analysis to guide the management of the
neck in patients with squamous cell carcinoma of the head and neck, Auris Nasus
Larynx 38 (2011) 702–709.
[14] M. Akbulut, Y. Ozbay, E. Ilkay, I. Karaca, N. Arslan, Effects of spironolactone and met-
oprolol on QT dispersion in heart failure, Jpn. Heart J. 44 (2003) 681–692.
[15] A. Boccanelli, G.F. Mureddu, G. Cacciatore, F. Clemenza, A. Di Lenarda, A. Gavazzi, M.
Porcu, R. Latini, D. Lucci, A.P. Maggioni, S. Masson, M. Vanasia, G. de Simone, A.I.-C.
Investigators, Anti-remodelling effect of canrenone in patients with mild chronic
heart failure (AREA IN-CHF study): ﬁnal results, Eur. J. Heart Fail. 11 (2009) 68–76.
[16] L. Bolondi, F. Piscaglia, A. Gatta, F. Salerno, M. Bernardi, A. Ascione, O. Ferrau, D.
Sacerdoti, S. Visentin, F. Trevisani, R. Mazzanti, G. Donati, U. Arena, P. Gentilini,D.O.C.S. Group, Effect of potassium canrenoate, an anti-aldosterone agent, on inci-
dence of ascites and variceal progression in cirrhosis, Clin. Gastroenterol. Hepatol.
4 (2006) 1395–1402.
[17] D.A. Calhoun, W.B. White, H. Krum, W. Guo, G. Bermann, A. Trapani, M.P. Lefkowitz,
J. Menard, Effects of a novel aldosterone synthase inhibitor for treatment of primary
hypertension: results of a randomized, double-blind, placebo- and active-controlled
phase 2 trial, Circulation 124 (2011) 1945–1955.
[18] M. Cicoira, L. Zanolla, A. Rossi, G. Golia, L. Franceschini, G. Brighetti, P. Marino, P.
Zardini, Long-term, dose-dependent effects of spironolactone on left ventricular
function and exercise tolerance in patients with chronic heart failure, J. Am. Coll.
Cardiol. 40 (2002) 304–310.
[19] A. Deswal, P. Richardson, B. Bozkurt, D.L. Mann, Results of the randomized aldoste-
rone antagonism in heart failure with preserved ejection fraction trial (RAAM-PEF),
J. Card. Fail. 17 (2011) 634–642.
[20] F. Edelmann, R. Wachter, A.G. Schmidt, E. Kraigher-Krainer, C. Colantonio, W.
Kamke, A. Duvinage, R. Stahrenberg, K. Durstewitz, M. Lofﬂer, H.D. Dungen, C.
Tschope, C. Herrmann-Lingen, M. Halle, G. Hasenfuss, G. Gelbrich, B. Pieske,
D.H.F.I. Aldo, Effect of spironolactone on diastolic function and exercise capacity in
patients with heart failure with preserved ejection fraction: the Aldo-DHF random-
ized controlled trial, JAMA 309 (2013) 781–791.
[21] H. Krum, H. Nolly, D. Workman, W. He, B. Roniker, S. Krause, K. Fakouhi, Efﬁcacy of
eplerenone added to renin-angiotensin blockade in hypertensive patients, Hyper-
tension 40 (2002) 117–123.
[22] C.S. Oxlund, J.E. Henriksen, L. Tarnow, K. Schousboe, J. Gram, I.A. Jacobsen, Low dose
spironolactone reduces blood pressure in patients with resistant hypertension and
type 2 diabetes mellitus: a double blind randomized clinical trial, J. Hypertens. 31
(2013) 2094–2102.
[23] B. Pitt, L. Kober, P. Ponikowski, M. Gheorghiade, G. Filippatos, H. Krum, C. Nowack, P.
Kolkhof, S.Y. Kim, F. Zannad, Safety and tolerability of the novel non-steroidal min-
eralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart fail-
ure and mild or moderate chronic kidney disease: a randomized, double-blind
trial, Eur. Heart J. 34 (2013) 2453–2463.
[24] B. Pitt, M.A. Pfeffer, S.F. Assmann, R. Boineau, I.S. Anand, B. Claggett, N. Clausell, A.S.
Desai, R. Diaz, J.L. Fleg, I. Gordeev, B. Harty, J.F. Heitner, C.T. Kenwood, E.F. Lewis, E.
O'Meara, J.L. Probstﬁeld, T. Shaburishvili, S.J. Shah, S.D. Solomon, N.K. Sweitzer, S.
Yang, S.M. McKinlay, T. Investigators, Spironolactone for heart failure with pre-
served ejection fraction, N. Engl. J. Med. 370 (2014) 1383–1392.
[25] B. Pitt, W. Remme, F. Zannad, J. Neaton, F. Martinez, B. Roniker, R. Bittman, S. Hurley, J.
Kleiman,M. Gatlin, E. Eplerenone Post-AcuteMyocardial InfarctionHeart Failure, I. Sur-
vival Study, Eplerenone, a selective aldosterone blocker, in patientswith left ventricular
dysfunction after myocardial infarction, N. Engl. J. Med. 348 (2003) 1309–1321.
[26] B. Pitt, F. Zannad, W.J. Remme, R. Cody, A. Castaigne, A. Perez, J. Palensky, J. Wittes,
The effect of spironolactone on morbidity and mortality in patients with severe
heart failure. Randomized Aldactone evaluation study investigators, N. Engl. J.
Med. 341 (1999) 709–717.
[27] S. Taheri, M. Mortazavi, A. Pourmoghadas, S. Seyraﬁan, Z. Alipour, S. Karimi, A pro-
spective double-blind randomized placebo-controlled clinical trial to evaluate the
safety and efﬁcacy of spironolactone in patients with advanced congestive heart fail-
ure on continuous ambulatory peritoneal dialysis, Saudi J. Kidney Dis. Transpl. 23
(2012) 507–512.
[28] J. Vaclavik, R. Sedlak, M. Plachy, K. Navratil, J. Plasek, J. Jarkovsky, T. Vaclavik, R.
Husar, E. Kocianova, M. Taborsky, Addition of spironolactone in patients with resis-
tant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-
controlled trial, Hypertension 57 (2011) 1069–1075.
[29] E. Vizzardi, A. D'Aloia, R. Giubbini, T. Bordonali, S. Bugatti, N. Pezzali, A. Romeo, A. Dei
Cas, M. Metra, C.L. Dei, Effect of spironolactone on left ventricular ejection fraction
and volumes in patients with class I or II heart failure, Am. J. Cardiol. 106 (2010)
1292–1296.
[30] E. Vizzardi, S. Nodari, G. Caretta, A. D'Aloia, N. Pezzali, G. Faden, C. Lombardi, R.
Raddino, M. Metra, C.L. Dei, Effects of spironolactone on long-term mortality and
morbidity in patients with heart failure and mild or no symptoms, Am. J. Med. Sci.
347 (2014) 271–276.
[31] W.B. White, A.A. Carr, S. Krause, R. Jordan, B. Roniker, W. Oigman, Assessment of the
novel selective aldosterone blocker eplerenone using ambulatory and clinical blood
pressure in patients with systemic hypertension, Am. J. Cardiol. 92 (2003) 38–42.
[32] F. Zannad, J.J. McMurray, H. Krum, D.J. van Veldhuisen, K. Swedberg, H. Shi, J.
Vincent, S.J. Pocock, B. Pitt, E.-H.S. Group, Eplerenone in patients with systolic
heart failure and mild symptoms, N. Engl. J. Med. 364 (2011) 11–21.
[33] D.J. Stuijver, E. Romualdi, B. van Zaane, L. Bax, H.R. Buller, V.E. Gerdes, A. Squizzato,
Under-reporting of venous and arterial thrombotic events in randomized clinical tri-
als: a meta-analysis, Intern. Emerg. Med. 10 (2015) 219–246.
[34] J.A. Ezekowitz, F.A.McAlister, Aldosterone blockade and left ventricular dysfunction:
a systematic review of randomized clinical trials, Eur. Heart J. 30 (2009) 469–477.
[35] T. Walter, S. Szabo, S. Kazmaier, T. Suselbeck, M. Borggrefe, H.M. Hoffmeister, Effect
of ACE inhibition on the ﬁbrinolytic system in patients requiring coronary artery by-
pass grafting, Thorac. Cardiovasc. Surg. 57 (2009) 368–371.
[36] K.O. Boman, J.H. Jansson, K.A. Nyhlen, T.K. Nilsson, Improved ﬁbrinolysis after one
year of treatment with enalapril in men and womenwith uncomplicatedmyocardi-
al infarction, Thromb. Haemost. 87 (2002) 311–316.
[37] G.P. Jones, Spironolactone and risk of upper gastrointestinal events: causality re-
mains unconvincing, BMJ 333 (2006) 501.
